These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35263200)

  • 41. Suppression of adriamycin resistance in osteosarcoma by blocking Wnt/β-catenin signal pathway.
    Wu BQ; Cao Y; Bi ZG
    Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3185-3192. PubMed ID: 28770967
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
    Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
    Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.
    Li C; Thompson MA; Tamayo AT; Zuo Z; Lee J; Vega F; Ford RJ; Pham LV
    Oncotarget; 2012 Mar; 3(3):314-26. PubMed ID: 22447839
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.
    Gaurnier-Hausser A; Patel R; Baldwin AS; May MJ; Mason NJ
    Clin Cancer Res; 2011 Jul; 17(14):4661-71. PubMed ID: 21610150
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identification of differentially expressed proteins in chemotherapy-sensitive and chemotherapy-resistant diffuse large B cell lymphoma by proteomic methods.
    Liu Y; Zeng L; Zhang S; Zeng S; Huang J; Tang Y; Zhong M
    Med Oncol; 2013 Jun; 30(2):528. PubMed ID: 23504336
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
    Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
    Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients.
    Lim EL; Trinh DL; Scott DW; Chu A; Krzywinski M; Zhao Y; Robertson AG; Mungall AJ; Schein J; Boyle M; Mottok A; Ennishi D; Johnson NA; Steidl C; Connors JM; Morin RD; Gascoyne RD; Marra MA
    Genome Biol; 2015 Jan; 16(1):18. PubMed ID: 25723320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma.
    Zheng W; Lin Q; Issah MA; Liao Z; Shen J
    BMC Cancer; 2021 Aug; 21(1):927. PubMed ID: 34404374
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of the intrinsic apoptosis pathway downstream of caspase-9 activation causes chemotherapy resistance in diffuse large B-cell lymphoma.
    Cillessen SA; Hess CJ; Hooijberg E; Castricum KC; Kortman P; Denkers F; Vos W; van de Wiel MA; Schuurhuis GJ; Ossenkoppele GJ; Meijer CJ; Oudejans JJ
    Clin Cancer Res; 2007 Dec; 13(23):7012-21. PubMed ID: 18056177
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
    Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
    Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint.
    Zhao L; Liu Y; Zhang J; Liu Y; Qi Q
    Cell Death Dis; 2019 Sep; 10(10):731. PubMed ID: 31570691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma.
    Peng W; Wu J; Feng J
    Biomed Pharmacother; 2016 Apr; 79():188-93. PubMed ID: 27044827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting glycometabolic reprogramming to restore the sensitivity of leukemia drug-resistant K562/ADM cells to adriamycin.
    Zhang X; Chen J; Ai Z; Zhang Z; Lin L; Wei H
    Life Sci; 2018 Dec; 215():1-10. PubMed ID: 30473023
    [TBL] [Abstract][Full Text] [Related]  

  • 54. OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma.
    Dong H; Wang Q; Zhang G; Li N; Yang M; An Y; Xie L; Li H; Zhang L; Zhu W; Zhao S; Zhang H; Guo X
    Cancer Med; 2020 Mar; 9(5):1790-1797. PubMed ID: 31918459
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
    Hu S; Xu-Monette ZY; Balasubramanyam A; Manyam GC; Visco C; Tzankov A; Liu WM; Miranda RN; Zhang L; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Han van Krieken J; Huang Q; Huh J; Ai W; Ponzoni M; Ferreri AJ; Zhao X; Winter JN; Zhang M; Li L; Møller MB; Piris MA; Li Y; Go RS; Wu L; Medeiros LJ; Young KH
    Blood; 2013 Apr; 121(14):2715-24. PubMed ID: 23343832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
    Jiang Y; Lin J; Zhang J; Lu S; Wang C; Tong Y
    Pathol Res Pract; 2019 Dec; 215(12):152684. PubMed ID: 31679792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.
    Iqbal J; Meyer PN; Smith LM; Johnson NA; Vose JM; Greiner TC; Connors JM; Staudt LM; Rimsza L; Jaffe E; Rosenwald A; Ott G; Delabie J; Campo E; Braziel RM; Cook JR; Tubbs RR; Gascoyne RD; Armitage JO; Weisenburger DD; Chan WC
    Clin Cancer Res; 2011 Dec; 17(24):7785-95. PubMed ID: 21933893
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
    Wong KK; Gascoyne DM; Brown PJ; Soilleux EJ; Snell C; Chen H; Lyne L; Lawrie CH; Gascoyne RD; Pedersen LM; Møller MB; Pulford K; Murphy D; Green TM; Banham AH
    Leukemia; 2014 Feb; 28(2):362-72. PubMed ID: 23884370
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effect of arsenic trioxide combined with adriamycin on the proliferation and apoptosis of human lymphoma cells].
    Huang R; Li X; Huang X; Yang X; Li W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 34(6):515-22. PubMed ID: 19587434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.